This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:AVMXY AVITA MED LTD/S (AVMXY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVITA MED LTD/S Stock (OTCMKTS:AVMXY) 30 days 90 days 365 days Advanced Chart Get AVITA MED LTD/S alerts:Sign Up Key Stats Today's Range$7.89▼$7.8950-Day Range$7.89▼$7.8952-Week Range$1.06▼$8.58VolumeN/AAverage Volume183,275 shsMarket Capitalization$651.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Read More… Receive AVMXY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVITA MED LTD/S and its competitors with MarketBeat's FREE daily newsletter. Email Address AVMXY Stock News HeadlinesCantor maintains Avita stock Overweight with $19 targetFebruary 14, 2025 | msn.comAvita medical director Suzanne Crowe buys $6,390 in stockJanuary 30, 2025 | msn.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.June 3, 2025 | Crypto 101 Media (Ad)BTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)January 13, 2025 | markets.businessinsider.comAvita Medical (RCEL) Gets a Buy from Lake StreetJanuary 9, 2025 | markets.businessinsider.comAvita Medical (RCEL) Receives a Hold from BTIGJanuary 7, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Avita Medical (RCEL)December 24, 2024 | markets.businessinsider.comAvita Medical Says FDA Approved Recell GO MiniDecember 23, 2024 | marketwatch.comSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:AVMXY CIKN/A Webwww.avitamedical.com Phone661-367-9170FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.50 Quick Ratio5.33 Sales & Book Value Annual Sales$5.51 million Price / Sales118.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book30.35Miscellaneous Outstanding Shares82,620,000Free FloatN/AMarket Cap$651.87 million OptionableNot Optionable Beta1.28 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:AVMXY) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVITA MED LTD/S Please log in to your account or sign up in order to add this asset to your watchlist. Share AVITA MED LTD/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.